Hepatitis E vaccine landscape update 2025

HEV vaccines are essential for disease control, but unresolved issues limit broader use. Conflicting data on miscarriage risk require further investigation. Ongoing trials in Pakistan and South Africa will offer key data on safety in pregnancy, immunogenicity in children, and use in people with HIV. WHO prequalification of HEV 239 vaccine is critical to expand access globally.